---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059532"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:04:20.931365+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Metagenomi Q1 net loss $25.1M, cash $327.4M; regains base editing and RIGS rights from Moderna

## Summary
- Q1 net loss $25.1M ($1.19/share) vs $16.1M loss in Q1 2023; collaboration revenue $11.2M.
- Cash, equivalents and marketable securities $327.4M including $80.7M net IPO proceeds; runway into 2027.
- Regained full global rights to wholly-owned base editors and RIGS; terminated PH1 collaboration with Moderna.
- Hemophilia A program: development candidate nomination expected mid-2024; 12-month NHP durability data in 2H 2024.
- R&D expenses $31.4M (+56% YoY); base editors expanded genome targetability 5-fold vs SpCas9.

## SEC filing metadata
- accession: 0000950170-24-059532
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017024059532/0000950170-24-059532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017024059532/mgx-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059532
- JSON: https://secwatch.observer/filing/0000950170-24-059532.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059532.txt

## Key facts
- Earnings Releases
  Metagenomi Therapeutics, Inc. reported quarter ended March 31, 2024 results: revenue $11,159 thousand, net income Net loss of $(25,148) thousand, EPS $(1.19) per share.
  - Period: quarter ended March 31, 2024
  - Revenue: $11,159 thousand
  - Net income: Net loss of $(25,148) thousand
  - EPS: $(1.19) per share
  - Result: reported results
  source text: announced its financial results for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785279/000095017024059532/0000950170-24-059532-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.